

Organized by



in cooperation with



# 15-ICML

15th International Conference on Malignant Lymphoma  
Palazzo dei Congressi, Lugano, Switzerland, June 18-22, 2019

Printed by courtesy of




ONCOLOGY



# INDEX

- 3 Acknowledgements
- 7 General Information
- 10 15-ICML locations
- 14 Floorplans
- 20 Program at a Glance
- 25 Conference Schedule
- 56 15-ICML Transport Information
- 58 15-ICML Contacts



**SAVE THE DATE!**

**16-ICML**  
16<sup>th</sup> International Conference on Malignant Lymphoma

Palazzo dei Congressi  
Lugano (Switzerland)  
[www.lymphcon.ch](http://www.lymphcon.ch)

**SAVE THE DATE: June 15-19, 2021**

# ACKNOWLEDGEMENTS

## **INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA and FOUNDATION FOR THE INSTITUTE OF ONCOLOGY RESEARCH PRESIDENT**

Franco Cavalli, Bellinzona (Switzerland)

## **ORGANIZING COMMITTEE CHAIRMAN**

Michele Ghielmini, Bellinzona  
(Switzerland)

## **ORGANIZING COMMITTEE**

(based in Bellinzona, Switzerland)

Francesco Bertoni

Alden A. Moccia

Bertrand Nadel, Marseilles (France) –  
American Association for Cancer  
Research (AACR) representative

Fedro A. Peccatori, Milan (Italy) -  
European School of Oncology (ESO)  
representative

Davide Rossi

Anastasios Stathis

Georg Stüssi

Emanuele Zucca

## **ADVISORY BOARD CHAIRMAN**

James O. Armitage, Omaha, NE (USA)

## **ADVISORY BOARD**

Elias Campo, Barcelona (Spain)

Bruce D. Cheson, Washington, D.C. (USA)

Nicholas Chiorazzi, Manhasset, NY (USA)

Wee Joo Chng, Singapore (Singapore)

Riccardo Dalla-Favera, New York, NY (USA)

Stephan Dirnhofer, Basel (Switzerland)

Martin Dreyling, Munich (Germany)

Andreas Engert, Cologne (Germany)

Jonathan W. Friedberg, Rochester,  
NY (USA)

Gianluca Gaidano, Novara (Italy)

Philippe Gaulard, Créteil (France)

Mary K. Gospodarowicz, Toronto, ON  
(Canada)

Peter W.M. Johnson, Southampton (UK)

Brad S. Kahl, St. Louis, MO (USA)

Ralf Küppers, Essen (Germany)

John P. Leonard, New York, NY (USA)

T. Andrew Lister, London (UK)

Markus G. Manz, Zurich (Switzerland)

Ari M. Melnick, New York, NY (USA)

Koichi Ohshima, Kurume (Japan)

Astrid Pavlovsky, Buenos Aires (Argentina)

Leticia Quintanilla-Martinez de Fend,  
Tübingen (Germany)

S.Vincent Rajkumar, Rochester, MN (USA)

Kerry J. Savage, Vancouver BC (Canada)

John F. Seymour, Melbourne (Australia)

Margaret A. Shipp, Boston, MA (USA)

Lena Specht, Copenhagen (Denmark)

Catherine Thieblemont, Paris (France)

Umberto Vitolo, Turin (Italy)

Anas Younes, New York, NY (USA)

Wilhelm Wössmann, Hamburg (Germany)

Weili Zhao, Shanghai (China)

## **CONFERENCE SECRETARIAT AND LOCAL ORGANISATION**

Cristiana Brentan, Orietta Lugli,

Chiara Saporiti,

Bellinzona (Switzerland)

**THE CONFERENCE ORGANISERS WISH TO THANK THE FOLLOWING SPONSORS FOR THEIR UNRESTRICTED FINANCIAL SUPPORT:**

(updated on May 2019)

AbbVie  
Acerta Pharma, a member of the AstraZeneca group  
Affimed  
AstraZeneca  
Atara Biotherapeutics Switzerland GmbH  
Bayer  
Bristol-Myers Squibb  
Celgene Corporation  
Celltrion Healthcare  
Gilead Sciences  
HTG Molecular Diagnostics

Incyte Corporation  
IQone, a Clinigen company  
Janssen Pharmaceutical Companies of Johnson & Johnson  
Karyopharm Therapeutics  
Kite, a Gilead Company  
Lymphoma Hub  
Loxo Oncology  
MorphoSys  
MSD  
Mundipharma International Limited  
Nordic Nanovector  
Novartis Oncology  
Pfizer Oncology  
Roche  
Sandoz  
Stemline Therapeutics  
Takeda Oncology

**THE CONFERENCE ORGANISERS WISH TO THANK THE FOLLOWING CONTRIBUTORS FOR THEIR SUPPORT:**

(updated on May 2019)

American Association for Cancer Research – AACR  
City of Lugano  
European Canine Lymphoma Network  
European School of Multimodality Imaging & Therapy – ESMIT  
European School of Oncology – ESO  
European Society for Medical Oncology – ESMO  
IBSA Foundation for Scientific Research  
International Extranodal Lymphoma Study Group – IELSG  
International Lymphoma Radiation Oncology Group - ILROG  
Kompetenznetz Maligne Lymphome e.V. – KML  
Leukemia & Lymphoma Society – LLS  
Lymphome.ch Patientennetz Schweiz  
San Salvatore Foundation  
Saudi Society of Blood & Marrow Transplantation – SS-BMT  
Swiss Cancer League  
Swiss Cancer Research Foundation  
Ticino Tourism  
Union for China Lymphoma Investigators – UCLI  
Università della Svizzera Italiana – USI

## ONSITE CONTACT DETAILS

### 15-ICML Registration and Information Desk

Monday, June 17:	only by appointments, only for groups
from Tuesday, June 18 to Friday, June 21:	07:30 – 20:00
Saturday, June 22:	07:30 – 14:00



### Contacts during the Conference

• Cristiana Brentan ( <i>scientific program and general information</i> )	+41 76 750 54 65 cristiana.brentan@lymphcon.ch
• Orietta Lugli ( <i>exhibition, satellite symposia, ancillary meetings</i> )	+41 79 800 24 45 orietta.lugli@lymphcon.ch
• Chiara Saporiti ( <i>registrations and accounting</i> )	+41 58 866 66 68 registration@lymphcon.ch

**Please consider that during the Conference days we will have few chances to check our messages: do not use e-mail for urgencies!**

## PALAZZO DEI CONGRESSI

The following services will be available in Palazzo dei Congressi:

- Internet Corner, sponsored by 
- Speaker Preview Center
- Transport Info Desk, for information on public transports and 15-ICML bus service  
**ph. +41 58 866 66 70**
- Amiconi Consulting SA info desk, for information on hotel accommodation, private transfer services and ICML Climate Protection Run.
- Currency exchange office (cash only) – the closest automatic cash dispenser / ATM is Cornèr Bank, via Canova 16
- Free refreshment points with water supply, sponsored by 
- Restrooms: Palazzo dei Congressi → basement, level -1 and restaurant  
“Villa Ciani” → basement  
Il Ciani Building → ground floor  
Marquee Parco Corso → close to the Overflow Area entrances  
Cinema Corso  
USI Università

# Striving to outsmart cancer. Together.



At AbbVie, we build bonds with oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

## GENERAL INFORMATION

15-ICML ONLINE RESOURCES → [ICML2019.lymphcon.ch](http://ICML2019.lymphcon.ch)

15-ICML WEBCAST, supported by  **Acerta Pharma**

A member of the AstraZeneca Group

Videos of the following sessions:

Keynote Lectures (H. Kaplan, G. Bonadonna, J. Ultmann Lectures)

Educational Sessions (Meet the Professor sessions and Educational Symposia)

15-ICML Highlights – “Take Home Messages”

will be available online for 15-ICML attendees (please note that the registration ID code, printed on personal badge, will be required).

The videos of these sessions will be provided free of charge, thanks to an unrestricted grant of ACERTA PHARMA, a member of the AstraZeneca Group, as of mid July 2019.

### 15-ICML SLIDES-SET PLATFORM

Slides-sets of presentations of all scientific sessions will be available, where speaker permission is granted, to 15-ICML attendees.

They will have the possibility to purchase online – upon payment of a CHF 50 fee – access to the slides-sets platform as of Monday, June 24 at [ICML2019.lymphcon.ch](http://ICML2019.lymphcon.ch).

### Online Evaluation Form - Certificate of attendance

15-ICML has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **30** European CME credits (ECMEC®s).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Certificate of Attendance will be available online at [ICML2019.lymphcon.ch](http://ICML2019.lymphcon.ch), from Monday, June 24 to Friday, July 19.

15-ICML registered attendees will be asked to enter the registration ID code, printed on personal badge, and complete the Evaluation Form.



15-ICML is accredited by the European Society for Medical Oncology (ESMO) with 25 ESMO-MORA cat. 1 points.



### Collaboration with the European School of Oncology (ESO)

The 15-ICML program will be part of the fourth edition of the Certificate of Competence in Lymphoma, a 14 months ECTS program developed by the European School of Oncology (ESO) and academically recognized by the Ulm University. The aim of the Certificate of Competence is to provide a curriculum of studies to advance knowledge and science in the management of lymphoma patients.

Further information can be obtained by visiting [www.eso.net](http://www.eso.net)

### 15-ICML Educational Book

Articles of the Educational Symposia and Meet the Professor sessions are included in the 15-ICML Educational Book, supplement to “Hematological Oncology” and published by Wiley. The supplement is distributed to attendees on site and also available online at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>).

### 15-ICML Abstract Book

All selected abstracts are included in the 15-ICML Abstract Book, published by Wiley and available online at the ICML website ([www.lymphcon.ch](http://www.lymphcon.ch)) and at the Wiley Online Library website (<http://onlinelibrary.wiley.com>).



**krebsliga schweiz**  
**ligue suisse contre le cancer**  
**lega svizzera contro il cancro**

**krebsforschung schweiz**  
**recherche suisse contre le cancer**  
**ricerca svizzera contro il cancro**  
**swiss cancer research**

### Travel Grants

Ten Travel Grants, sponsored by the Swiss Cancer League and by the Swiss Cancer Research Foundation, have been assigned to the following young investigators, on the basis of the abstract evaluation results (rank order by score):

E. Tausch, Ulm (Germany)	Presentation nr 047
L.K. Hilton, Burnaby, B.C. (Canada)	Presentation nr 036
C. Rushton, Burnaby, B.C (Canada)	Presentation nr 004
J. Gauthier, Seattle, WA (USA)	Presentation nr 120
E.A. Chong, Philadelphia, PA (USA)	Presentation nr 090
O. Al-Sawaf, Cologne (Germany)	Presentation nr 062
A. Hayden, Vancouver, B.C. (Canada)	Presentation nr 107
M.S. Binkley, Stanford, CA (USA)	Presentation nr 097
P. Ghione, New York, NY (USA)	Presentation nr 056
B. Donati, Reggio Emilia (Italy)	Presentation nr 017





**Visit our booth**  
to learn how we're  
**transforming**  
**cancer treatment**



## 15-ICML LOCATIONS



**Palazzo  
dei Congressi**  
Piazza  
Indipendenza 4

Registration desk, scientific program (rooms A and B), satellite symposia, meeting rooms C1, C2, C3, D, E, G and H. Transport Info Desk and Amiconi Consulting SA Desk  
Services: wi-fi, internet corner, buvette, water dispensers, cloakroom, restrooms.



**“Marquee Parco Ciani”** Poster Session, room B  
Parco Civico  
overflow area, meeting rooms 18  
and 19, exhibition area,  
lunches & coffee breaks.  
Services: wi-fi, water dispensers,  
restrooms.



**Villa Ciani**  
Via Canova  
Parco Civico  
Meeting rooms 1 – 10,  
Sit & Meet area.  
Services: wi-fi, water dispenser,  
restrooms.



**Il Ciani building**  
Viale C. Cattaneo 5  
Meeting rooms 11 – 17,  
Sit & Meet area.  
Services: wi-fi, water dispenser,  
restrooms.



**USI – Università**  
Via G. Buffi 13  
Parallel scientific sessions, room A  
overflow area, satellite symposia.  
Services: wi-fi, water dispenser  
and restrooms.



**Cinema Corso**  
Via G. B. Pioda 4  
Parallel scientific sessions, room A  
overflow area, satellite symposia.  
Services: wi-fi, water dispenser  
and restrooms.



**Campo Marzio Parking** 15-ICML bus service parking  
Via Campo Marzio



15-ICML is proud to compensate its greenhouse gas emissions investing in the carbon offset project: **“Paradigm Cookstoves and Water, Kenya”**, a step towards mitigating climate change globally and a contribution to the Sustainable Development Goals set out by the United Nations.

This multi-technology project distributes both efficient cookstoves and water purification devices to local communities in Kenya. Its aim is to provide safe water and clean indoor air to improve livelihoods in East Africa, while at the same time preventing deforestation.



**PARADIGM PROJECT KENYA**

Ameliorating rural poverty with energy-efficient cookstoves and safe water technology

This multi-technology project distributes both efficient cookstoves and water purification devices to local communities in Kenya. Its aim is to provide safe water and clean indoor air to improve livelihoods in East Africa, while at the same time preventing deforestation.

Project 301 260 | 11/2016, 07/2018

southpole.com/projects

**The Context**  
Most Kenyan households spend a significant amount of time and income procuring fuel to cook and boil water. The continued collection of firewood by local people in Paradigm target locations is exhausting local wood supplies and causing deforestation. Community members must consequently travel further more than 15 kilometres from their towns to collect fuel – in some cases, mothers are away from their young children and nursing infants for many hours.

**The Project**  
The Paradigm project distributes more efficient stoves and clean water technologies to Kenyan communities. Families now require less wood fuel to cook and purify water supplies, and pressures on the surrounding forests are eased. Replacing traditional cookstoves with locally-manufactured, efficient stoves reduces fuel use by about 50%, and decreases toxic emissions by up to 70%.

**The Benefits**  
By distributing these modern efficient cookstoves, the Paradigm project creates household savings of up to 15% – money that can instead go towards food, school fees, and other essentials. Improved indoor air quality significantly reduces cases of respiratory disease and pneumonia, and women are empowered by financial and time-savings. Safe water filters and community dispensers prevent water-borne diseases, and the project also creates local employment opportunities for communities.

**Tackling health issues, empowering women, and reducing community dependence on non-renewable woody biomass.**

**SUSTAINABLE GOALS**  
12 Climate Action

**660,000 people**  
with improved health due to reduced indoor smoke pollution

**28 full-time jobs**  
provided for local people who are trained by Paradigm

**65,000+ efficient cookstoves**  
delivered to date, reducing the amount of wood required for cooking

**484,746 tCO<sub>2</sub>e**  
mitigated on average annually by avoided deforestation and reduced emissions

**50% less wood**  
needed for cooking and boiling, reducing pressures on healthy forests

**Gold Standard**

For more information on the UK Sustainable Development Goals, please visit [www.gov.uk/sustainable-development-goals](http://www.gov.uk/sustainable-development-goals)  
For more information on the UK Sustainable Development Goals, please visit [www.15degrees.com/uk/sustainable-development-goals](http://www.15degrees.com/uk/sustainable-development-goals) | Registry ID: 1844

**#READYFOR2020** Visit [www.15degrees.com/ready](http://www.15degrees.com/ready) to find your local office or call our Headquarters in Zurich on +41 43 741 35 10

Copyright © 2018 South Pole. All information contained herein is subject to change without notice. South Pole Group shall not be liable for technical or editorial errors or omissions contained herein.

# ICML Climate Protection Run, 1st edition Lugano – Thursday, June 20, 2019 – h 20:30

15-ICML is proud to announce the first ever ICML Climate Protection Run, possible thanks to the valuable contribution of



*Wholly owned subsidiary  
of Eli Lilly and Company*



ON SITE INFO

Its proceeds will be used for the above already committed project in Kenya.

A beautiful and easy 5 km running trail which goes from Via Foce (bibs to be collected at the Padiglione Conza by the Campo Marzio: ICML bus parking), to the Ciani park, stretches along the Lugano lake up to the Paradiso area and comes back.

Pasta Party and awards ceremony will be at Padiglione Conza from 21:00.

For information related to the next edition of the ICML Climate Protection Run (June 2021), please contact the local agent Amiconi Consulting SA by sending an e-mail to [info@amiconiconsulting.ch](mailto:info@amiconiconsulting.ch).



Complimentary internet wi-fi access is available for conference delegates throughout the venue.

To access wi-fi, please use the following information:

**network name (SSID): 15-ICML**

**password (PSK): Lugano2019**



Please note that wi-fi connection speed and performance depend on number of simultaneous accesses.

The 15-ICML Application is available thanks to



**A member of the AstraZeneca Group**

It can be downloaded from the Apple App Store or Google Play.

# MARQUE PARCO CIANI


Poster Session

Room B Overflow Area

Meeting Rooms 18 and 19

Exhibition Area

Coffee and Lunch Area



## OPENING HOURS

Wednesday June 19	09:00 – 17:00
Thursday June 20	09:00 – 17:00
Friday June 21	09:00 – 18:30

*Restrooms and Water Dispensers are available*

## VILLA CIANI

Meeting Rooms nr 1- 10  
Sit&Meet Area

### OPENING HOURS

from Tuesday, June 18 to Friday, June 21 from 08:00 to 20:00

### GROUND FLOOR

Meeting Room nr 1	NOVARTIS ONCOLOGY
Meeting Rooms nr 2 & 3	TAKEDA ONCOLOGY
Meeting Rooms nr 4 & 5	GILEAD SCIENCES and KITE, A GILEAD COMPANY
Meeting Room nr 6	BAYER

### FIRST FLOOR


Meeting Rooms nr 7 & 8	CELGENE CORPORATION
------------------------	---------------------

### SECOND FLOOR


Meeting Room nr 9	ROCHE
Meeting Room nr 10	MUNDIPHARMA INTERNATIONAL LIMITED
Sit&Meet Area	

*Restrooms and Water Dispensers are available at level - 1*


Villa Ciani ground floor








Villa Ciani second floor



# IL CIANI

Meeting Rooms nr 11 - 17  
Sit&Meet Area



## OPENING HOURS

from Tuesday, June 18 to Friday, June 21 from 07:00 to 21:00  
Saturday, June 22 from 07:00 to 18:00

Meeting Room nr 11	GILEAD SCIENCES AND KITE, A GILEAD COMPANY
Meeting Rooms nr 12 and 13	CELGENE CORPORATION
Meeting Room nr 4	LOXO ONCOLOGY
Meeting Room nr 5	ACERTA PHARMA, A MEMBER OF THE ASTRAZENECA GROUP
Meeting Room nr 6	INCYTE CORPORATION
Meeting Room nr 7	NOVARTIS ONCOLOGY

*Restrooms and Water Dispensers are available*

## PROGRAM AT A GLANCE

TUESDAY, JUNE 18					
	ROOM A PCL GROUND FLOOR	ROOM B I PCL FIRST FLOOR	ROOM B II PCL FIRST FLOOR	AUDITORIUM USI UNIVERSITÀ	AULA MAGNA USI UNIVERSITÀ
7:15					
7:30					
7:45					
8:00					
8:15					
8:30					
8:45					
9:00					
9:15					
9:30					
9:45					
10:00					
10:15					
10:30					
10:45					
11:00					
11:15					
11:30					
11:45					
12:00					
12:15					
12:30					
12:45					
13:00					
13:15					
13:30					
13:45					
14:00					
14:15					
14:30					
14:45					
15:00					
15:15					
15:30					
15:45					
16:00					
16:15					
16:30					
16:45					
17:00					
17:15					
17:30					
17:45					
18:00					
18:15					
18:30					
18:45					
19:00					
19:15					
19:30					
19:45					
20:00					

**CLOSED WORKSHOP**  
organized in  
co-operation with  
American Association  
for Cancer Research  
– AACR and European  
School of Oncology  
– ESO  
and with the  
endorsement of the  
Leukemia & Lymphoma  
Society - LLS  
**by invitation only  
(08:30-17:10)**

**WORKSHOP - NEW  
GUIDELINES FROM  
THE INTERNATIONAL  
LYMPHOMA RADIATION  
ONCOLOGY GROUP - IIROG**  
organized by IIROG  
open to all 15-ICML  
participants  
(15:00-17:15)

**NOVARTIS  
ONCOLOGY  
symposium  
(16:00-17:30)**

**BRISTOL-MYERS  
SQUIBB  
symposium  
(16:00-17:30)**

**KITE, A GILEAD  
COMPANY  
symposium  
(16:00-17:30)**

**ROCHE  
symposium  
(18:30-20:00)**

**BAYER  
symposium  
(18:30-20:00)**

**TAKEDA ONCOLOGY  
symposium  
(18:30-20:00)**

**LYMPHOMA HUB  
symposium  
(18:30-20:00)**

WEDNESDAY, JUNE 19											
	ROOM A PCL GROUND FLOOR	ROOM B PCL FIRST FLOOR	MARQUEE PARCO CIANI	CINEMA CORSO	AUDITORIUM USI UNIVERSITÀ	AULA MAGNA USI UNIVERSITÀ					
7:15											
7:30											
7:45			<b>EXHIBITION AREA and POSTER SESSION (09:00-17:00)</b>								
8:00											
8:15											
8:30	Meet the Professor (8:30-9:15) <b>S.V. Rajkumar</b>	Meet the Professor (8:30-9:15) <b>S. Rule</b>	<b>POSTER SESSION SET UP (09:00-12:00)</b>	Meet the Professor (8:30-9:15) <b>S.S. Neelapu</b>	Meet the Professor (8:30-9:15) <b>T.T. Batchelor</b>	Meet the Professor (8:30-9:15) <b>W. Zhao</b>					
8:45											
9:00											
9:15											
9:30	Meet the Professor (9:30-10:15) <b>A. Davies</b>	Meet the Professor (9:30-10:15) <b>M. Hallek</b>			Meet the Professor (9:30-10:15) <b>W.H. Wilson</b>	Meet the Professor (9:30-10:15) <b>W. Kempf</b>	Meet the Professor (9:30-10:15) <b>L. De Leval</b>				
9:45											
10:00											
10:15			<b>COFFEE BREAK (10:15-10:35)</b>	<b>COFFEE BREAK (10:15-10:35)</b>	<b>COFFEE BREAK (10:15-10:35)</b>						
10:30											
10:45	<b>Educational Symposium A: HL (10:35-12:00) Room A - Cinema Corso - Aula Magna</b>	<b>Educational Symposium B: NHL (10:35-12:00) Room B - Marquee</b>	broadcasting of Educational Symposium B: NHL (10:35-12:00)	broadcasting of Educational Symposium A: HL (10:35-12:00)	broadcasting of Educational Symposium A: HL (10:35-12:00)	broadcasting of Educational Symposium A: HL (10:35-12:00)					
11:00											
11:15											
11:30											
11:45											
12:00			<b>LUNCH TIME and POSTER VIEWING (12:00-13:00)</b>								
12:15											
12:30											
12:45											
13:00	<b>Opening of the conference HENRY KAPLAN MEMORIAL LECTURE (13:00-14:00)</b>		broadcasting of Opening of the Conference Henry Kaplan Lecture	broadcasting of Opening of the Conference Henry Kaplan Lecture	broadcasting of Opening of the Conference Henry Kaplan Lecture	broadcasting of Opening of the Conference Henry Kaplan Lecture					
13:15											
13:30	Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna										
13:45											
14:00											
14:15	<b>PLENARY SESSION (14:00-15:25) Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna</b>		broadcasting of PLENARY SESSION	broadcasting of PLENARY SESSION	broadcasting of PLENARY SESSION	broadcasting of PLENARY SESSION					
14:30											
14:45											
15:00											
15:15											
15:30			<b>COFFEE BREAK (15:25-15:50)</b>								
15:45											
16:00	<b>AACR-ICML Joint Session (15:50-16:50)</b>		broadcasting of AACR-ICML Joint Session	broadcasting of AACR-ICML Joint Session	broadcasting of AACR-ICML Joint Session	broadcasting of AACR-ICML Joint Session					
16:15											
16:30	Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna										
16:45											
16:50											
17:00	"Focus on..." session <b>MANTLE CELL LYMPHOMA (17:05-18:05)</b>	"Focus on..." session <b>PET IMAGING (17:05-18:05)</b>	broadcasting of "Focus on..." session PET IMAGING	"Focus on..." session <b>PEDIATRIC LYMPHOMA (17:05-18:05)</b>	"Focus on..." session <b>RESULTS FROM SINGLE AGENT STUDIES (17:05-18:05)</b>	"Focus on..." session <b>ONGOING TRIALS (17:05-18:05)</b>					
17:15											
17:30											
17:45											
18:00											
18:15											
18:30											
18:45	<b>JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON &amp; JOHNSON symposium (18:30-20:00)</b>	<b>MEDSCAPE EDUCATION symposium (18:30-20:00) Supported by an independent educational grant from AbbVie</b>			<b>SANDOZ ONCOLOGY symposium (18:30-20:00)</b>						
19:00											
19:15											
19:30											
19:45											
20:00											

THURSDAY, JUNE 20						
	ROOM A PCL GROUND FLOOR	ROOM B PCL FIRST FLOOR	MARQUEE PARCO CIANI	CINEMA CORSO	AUDITORIUM USI UNIVERSITÀ	AULA MAGNA USI UNIVERSITÀ
7:15						
7:30						
7:45						
8:00	Meet the Professor (8:00-8:45) <b>S. Rule</b>	Meet the Professor (8:00-8:45) <b>S.V. Rajkumar</b>	<b>EXHIBITION AREA and POSTER SESSION 9:00-17:00</b>	Meet the Professor (8:00-8:45) <b>T.T. Batchelor</b>	Meet the Professor (8:00-8:45) <b>W.H. Wilson</b>	Meet the Professor (8:00-8:45) <b>B. Falini</b>
8:15						
8:30						
8:45						
9:00						
9:15	Case discussion session <b>DLBCL: BIOLOGY</b> E. Ginè Soca vs J.R. Westin (09:00-10:30)	<b>SESSION 1: DLBCL BIOLOGY</b> (9:00-10:30) Room B - Marquee	broadcasting of SESSION 1	Case discussion session <b>HODGKIN LYMPHOMA</b> A.M. Sureda Balari vs H.J. Lee (09:00-10:30)	Case discussion session <b>RADIOTHERAPY FOR LYMPHOMA</b> T. Illidge vs B.S. Dabaja (09:00-10:30)	Case discussion session <b>DIFFICULT PATHOLOGICAL CASES</b> A. Lopez-Guillermo vs R. Hagemeister (09:00-10:30)
9:30						
9:45						
10:00						
10:15						
10:30			<b>COFFEE BREAK (10:30-11:00)</b>	<b>COFFEE BREAK (10:30-11:00)</b>	<b>COFFEE BREAK (10:30-11:00)</b>	
10:45						
11:00	<b>SESSION 2: DLBCL: CLINICAL DATA</b> (11:00-12:00) Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna		broadcasting of SESSION 2	broadcasting of SESSION 2	broadcasting of SESSION 2	broadcasting of SESSION 2
11:15						
11:30						
11:45						
12:00						
12:15			<b>LUNCH TIME and POSTER VIEWING</b> (12:00-13:00)			
12:30						
12:45						
13:00	<b>GIANNI BONADONNA MEMORIAL LECTURE</b> (13:00-13:45) Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna		broadcasting of Gianni Bonadonna Lecture	broadcasting of Gianni Bonadonna Lecture	broadcasting of Gianni Bonadonna Lecture	broadcasting of Gianni Bonadonna Lecture
13:15						
13:30						
13:45						
14:00	<b>SESSION 3: CLL</b> (13:45-15:15) Room A - B - Marquee - Cinema Corso - Auditorium - Aula Magna		broadcasting of SESSION 3	broadcasting of SESSION 3	broadcasting of SESSION 3	broadcasting of SESSION 3
14:15						
14:30						
14:45						
15:00						
15:15			<b>COFFEE BREAK (15:15-15:40)</b>			
15:30						
15:45	<b>SESSION 4: Treatment with novel antibodies</b> (15:40-16:55) Room A - Cinema Corso - Auditorium - Aula Magna		broadcasting of SESSION 5	broadcasting of SESSION 4	broadcasting of SESSION 4	broadcasting of SESSION 4
16:00						
16:15						
16:30						
16:45						
16:55						
17:00	<b>SESSION 5: T-Cell Lymphoma</b> (15:40-16:55) Room B - Marquee		broadcasting of "Focus on..." session <b>CHEMOTHERAPY- FREE STRATEGIES</b> (17:05-18:05)	"Focus on..." session <b>PRECLINICAL AND EARLY CLINICAL DATA</b> (17:05-18:05)	"Focus on..." session <b>NON-CLINICAL NEW DRUGS</b> (17:05-18:05)	"Focus on..." session <b>HIGH RISK DLBCL</b> (17:05-18:05)
17:15	"Focus on..." session <b>CLL AND MORE</b> (17:05-18:05)	"Focus on..." session <b>CHEMOTHERAPY- FREE STRATEGIES</b> (17:05-18:05)	broadcasting of "Focus on..." session <b>CHEMOTHERAPY- FREE STRATEGIES</b> (17:05-18:05)	"Focus on..." session <b>PRECLINICAL AND EARLY CLINICAL DATA</b> (17:05-18:05)	"Focus on..." session <b>NON-CLINICAL NEW DRUGS</b> (17:05-18:05)	"Focus on..." session <b>HIGH RISK DLBCL</b> (17:05-18:05)
17:30						
17:45						
18:00						
18:15						
18:30						
18:45						
19:00	<b>CELGENE symposium</b> (18:30-20:00)	<b>MORPHOSYS symposium</b> (18:30-20:00)				
19:15						
19:30						
19:45						
20:00						

**FRIDAY, JUNE 21**

	ROOM A PCL GROUND FLOOR	ROOM B PCL FIRST FLOOR	MARQUEE PARCO CIANI	CINEMA CORSO	AUDITORIUM USI UNIVERSITÀ	AULA MAGNA USI UNIVERSITÀ	
7:15							
7:30							
7:45							
8:00	Meet the Professor (8:00-8:45) <b>M. Hallek</b>	Meet the Professor (8:00-8:45) <b>A. Davies</b>	<b>EXHIBITION AREA and POSTER SESSION (9:00-18:30)</b>	Meet the Professor (8:00-8:45) <b>W. Kempf</b>	Meet the Professor (8:00-8:45) <b>S.S. Neelapu</b>	Meet the Professor (8:00-8:45) <b>L. Quintanilla W. Wössmann</b>	
8:15							
8:30							
8:45							
9:00	Case discussion session: <b>FL/INDOLENT LYMPHOMA</b>	<b>SESSION 6: Lymphoma Pathology (9:00-10:30)</b> Room B - Marquee	broadcasting of SESSION 6 (9:00-10:30)	Case discussion: <b>CLL</b> J. Delgado vs P.A. Thompson (09:00-10:30)	<b>WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES</b> organized by International Lymphoma Radiation Oncology Group - IIROG open to all 15-ICML participants (9:00-12:00)	Case discussion session: <b>PTCL</b> A. Martin vs N.H. Fowler (09:00-10:30)	
9:15	M. Provencio Pulla vs L.J. Nastoupil (09:00-10:30)						
9:30							
9:45							
10:00							
10:15							
10:30			<b>COFFEE BREAK (10:30-11:00)</b>	<b>COFFEE BREAK (10:30-11:00)</b>		<b>COFFEE BREAK (10:30-11:00)</b>	
10:45							
11:00	<b>SESSION 7: HODGKIN LYMPHOMA (11:00-12:00)</b>		broadcasting of SESSION 7	broadcasting of SESSION 7		broadcasting of SESSION 7	
11:15	Room A - B - Marquee - Cinema Corso - Aula Magna						
11:30							
11:45							
12:00			<b>LUNCH TIME and POSTER VIEWING (12:00-13:00)</b>				
12:15							
12:30							
12:45							
13:00	<b>JOHN ULTMANN MEMORIAL LECTURE (13:00 -13:45)</b> Room A - B - Marquee - Cinema Corso - Aula Magna		broadcasting of John Ultmann Lecture	broadcasting of John Ultmann Lecture	broadcasting of John Ultmann Lecture		
13:15							
13:30							
13:45	<b>SESSION 8: FOLLICULAR LYMPHOMA (13:45 -15:00)</b> Room A - Cinema Corso	<b>SESSION 9: EXTRANODAL LYMPHOMAS (13:45-15:00)</b> Room B - Marquee	broadcasting of SESSION 9	broadcasting of SESSION 8	<b>IBSA FOUNDATION SPECIAL FORUM: "Revolutionary therapies for cancer"</b> <i>free and open to all 15-ICML participants - appreciated pre-registration at <a href="http://www.ibsafoundation.org">www. ibsafoundation.org</a> (14:15-17:30)</i>	<b>UCL - ICML JOINT SESSION "New data on T-Cell and other Lymphomas" (14:15-17:15)</b>	
14:00							
14:15							
14:30							
14:45							
15:00			<b>COFFEE BREAK (15:00-15:30)</b>				
15:15							
15:30	<b>REPORT OF THE 15-ICML CLOSED WORKSHOP (15:30-15:45)</b>		broadcasting of Report	broadcasting of Report			
15:45							
16:00	<b>SESSION 10: ADVANCES IN CAR-T CELL TREATMENT (15:45-17:15)</b> Room A - B - Marquee and Cinema Corso		broadcasting of SESSION 10	broadcasting of SESSION 10			
16:15							
16:30							
16:45							
17:00							
17:15	<b>SPECIAL LECTURE S.V. Rajkumar (17:15 -17:35)</b>		broadcasting of SPECIAL LECTURE	broadcasting of SPECIAL LECTURE			
17:30							
17:45			<b>FAREWELL APERITIF (17:35-18:30)</b>				
18:00							
18:15							
18:30	<b>IOSI - THE BIG DEBATE (18:30-19:30)</b>						
18:45	Supported by Gilead Sciences who provided funding						
19:00							
19:15							
19:30							
19:45							
20:00							

SATURDAY, JUNE 22			
	ROOM A PCL GROUND FLOOR	ROOM B PCL FIRST FLOOR	AUDITORIUM USI UNIVERSITÀ
7:15			
7:30			
7:45			
8:00			
8:15			
8:30	<p style="text-align: center;"><b>SESSION 11: NEW DRUG COMBINATIONS</b> (08:30-10:00) Room A - B</p>		<p style="text-align: center;">ESO - ESMIT EDUCATIONAL SESSION <b>"PET-CT IN LYMPHOMA"</b> open to all 15-ICML attendees (8:30-10:30)</p>
8:45			
9:00			
9:15			
9:30			
9:45			
10:00	<p style="text-align: center;"><b>"FOCUS ON..." SESSIONS:</b> <b>Indolent non-follicular Lymphoma</b> Room A - B (10:15 - 11:15)</p>		
10:15			
10:30			
10:45			
11:00			
11:15			
11:30	<p style="text-align: center;"><b>15-ICML HIGHLIGHTS</b> "Take Home Messages" (11:15-11:40)</p>		
11:45			
12:00	<p style="text-align: center;">CLOSURE AND FAREWELL (11:40-11:50)</p>		
12:15			
12:30			
12:45			
13:00			
13:15			
13:30	<p style="text-align: center;"><b>IV International Workshop on Canine Lymphoma</b> Organized by the European Canine Lymphoma Network <i>open to all 15-ICML attendees</i> (13:30 - 18:00)</p>		
13:45			
14:00			
14:15			
14:30			
14:45			
15:00			
15:15			
15:30			
15:45			
16:00			
16:15			
16:30			
16:45			
17:00			
17:15			
17:30			
17:45			
18:00			
18:15			
18:30			
18:45			
19:00			
19:15			
19:30			
19:45			
20:00			



# CONFERENCE SCHEDULE

Tuesday, June 18, 2019

TUESDAY

08:30 – 17:10 Auditorium (USI Università)	<b>CLOSED WORKSHOP – BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE</b> Co-chairs: D. Rossi, Bellinzona (Switzerland), W.H. Wilson, Bethesda, MD (USA) and E. Zucca, Bellinzona (Switzerland) Organized in co-operation with the American Association for Cancer Research – AACR and the European School of Oncology – ESO and with the endorsement of the Leukemia & Lymphoma Society – LLS <b>by invitation only</b>
13:30 – 15:00	<i>2 parallel symposia</i>
Room B I	KITE, A GILEAD COMPANY <b>CAR T: FROM BED TO BENCH AND BACK AGAIN</b> Chair: C. Roddie, London (UK)
Room B II	PFIZER ONCOLOGY <b>RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO FOSTER INNOVATION IN LYMPHOMA TREATMENT</b> Chair: J. Sharman, Eugene, OR (USA)
15:00 – 17:15 Aula Magna (USI Università)	<b>WORKSHOP – NEW GUIDELINES FROM THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP - ILROG</b> Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG <b>open to all 15-ICML attendees</b>
	<b>PART 1 – NEW GUIDELINES FROM ILROG</b> Chair: L. Specht, Copenhagen (Denmark)
15:00	RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA A. Ng, Boston, MA (USA)
15:15	SOLITARY PLASMACYTOMA AND MULTIPLE MYELOMA R. Tsang, Toronto (Canada)
15:30	IMAGING IN RADIATION THERAPY FOR LYMPHOMA G. Mikhaeel, London (UK)
15:45	PROTON THERAPY FOR MEDIASTINAL LYMPHOMAS B.S. Dabaja, Houston, TX (USA)
16:00	DISCUSSION

16:15	<b>COFFEE BREAK</b> <i>inside Aula Magna (USI Università), for attendees</i>
	<b>PART 2 – PANEL DISCUSSION</b> Led by J. Plastaras, Philadelphia, PA (USA)
16:30	FUTURE GUIDELINES TO BE DEVELOPED; ISSUES TO BE CONSIDERED IN ILROG GUIDELINES
16:50	HOW TO DISSEMINATE AND USE ILROG GUIDELINES
16:00 – 17:30	<i>3 parallel symposia</i>
Room A	NOVARTIS ONCOLOGY <b>MAXIMIZING CLINICAL BENEFIT IN LYMPHOMAS: EXPLORING THE UTILITY OF CAR T-CELL THERAPY</b> Chair: U. Jaeger, Vienna (Austria)
Room B I	BRISTOL-MYERS SQUIBB <b>RATIONALE: RESEARCH AND NEW THERAPEUTIC APPROACHES – I-O NOVEL AGENTS ADVANCING LYMPHOMA EXPECTATIONS</b> Chair: P.L. Zinzani, Bologna (Italy)
Room B II	KITE, A GILEAD COMPANY <b>CAR T THERAPY: A CLOSER LOOK AT THE SCIENCE BEHIND THE CELLS</b> Chair: M. Topp, Würzburg (Germany)
18:30 – 20:00	<i>4 parallel symposia</i>
Room A	ROCHE <b>ANTIBODY THERAPIES FOR PATIENTS WITH DLBCL: WHAT DOES THE FUTURE HOLD?</b> Chair: L. Sehn, Vancouver B.C. (Canada)
Room B I	BAYER <b>PRECISION MEDICINE IN MALIGNANT LYMPHOMA: IS IT A REALITY?</b> Chair: M. Ghilmini, Bellinzona (Switzerland)
Room B II	TAKEDA ONCOLOGY <b>ON THE FRONTLINE: MANAGING PATIENTS WITH CD30+ HL AND PTCL</b> Chair: M. Hutchings, Copenhagen (Denmark)
Auditorium USI Università	LYMPHOMA HUB <b>NEW CHEMOTHERAPY-FREE APPROACHES FOR THE TREATMENT OF LYMPHOID MALIGNANCES</b> Chair and co-chair: G. Salles, Lyon (France) and A. Younes, New York, NY (USA)

## Wednesday, June 19, 2019

08:30 – 09:15	Article Nr	<b>“MEET THE PROFESSOR” SESSIONS</b> 🎤 <i>5 parallel sessions</i>
Room A	EB09	MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD? S.V. Rajkumar, Rochester, MN (USA) <i>repeated on Thursday, June 20, in Room B</i>
Room B	EB10	THE MODERN APPROACH TO MANTLE CELL LYMPHOMA S. Rule, Plymouth (UK) <i>repeated on Thursday, June 20, in Room A</i>
Cinema Corso	EB07	MANAGING THE TOXICITIES OF CAR T-CELL THERAPY S.S. Neelapu, Houston, TX (USA) <i>repeated on Friday, June 21, in Auditorium (USI Università)</i>
Auditorium (USI Università)	EB01	PCNSL, A CURABLE DISEASE T.T. Batchelor, Boston, MA (USA) <i>repeated on Thursday, June 20, in Cinema Corso</i>
Aula Magna (USI Università)	EB12	WHAT WE SHOULD KNOW ABOUT NK/T-CELL LYMPHOMAS W. Zhao, Shanghai (China) <i>offered only once</i>
09:00 – 12:00 Marquee		<b>POSTER SESSION SET UP</b>
09:00 - 17:00		<b>OPENING OF EXHIBITION AREA</b>
09:30 – 10:15		<i>5 parallel sessions</i>
Room A	EB02	DOUBLE HIT LYMPHOMA, SO WHAT? A. Davies, Southampton (UK) <i>repeated on Friday, June 21, in Room B</i>
Room B	EB05	HOW TO APPROACH CLL IN CLINICAL PRACTICE M. Hallek, Cologne (Germany) <i>repeated on Friday, June 21, in Room A</i>
Cinema Corso	EB11	LIQUID BIOPSY IN NON-HODGKIN'S LYMPHOMA W.H. Wilson, Bethesda, MD (USA) <i>repeated on Thursday, June 20, in Auditorium (USI Università)</i>
Auditorium (USI Università)	EB06	CUTANEOUS LYMPHOMAS W. Kempf, Zurich (Switzerland) <i>repeated on Friday, June 21, in Cinema Corso</i>

Aula Magna (USI Università)	EB03	BREAST IMPLANT ASSOCIATED ALCL AND OTHER RARE T-CELL LYMPHOMAS L. de Leval, Lausanne (Switzerland) <i>offered only once</i>
<b>COFFEE BREAK</b>		
10:15 – 10:35 Marquee, Cinema Corso and USI Università		
10:35 – 12:00		
<b>EDUCATIONAL SYMPOSIA</b> 🎬		
<i>2 parallel sessions</i>		
<b>TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM</b>		
Chair: A. Engert, Cologne (Germany)		
Room A, Cinema Corso, Auditorium and Aula Magna (USI Università)	EB13	OPTIONS FOR FIRST LINE THERAPY OF HODGKIN LYMPHOMA P.W.M. Johnson, Southampton (UK)
	EB14	RELAPSED AND REFRACTORY DISEASE A.S. LaCasce, Boston, MA (USA)
	EB15	TREATMENT OF ELDERLY HODGKIN LYMPHOMA PATIENTS A. Engert, Cologne (Germany)
<b>NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY</b>		
Chair: G. Salles, Lyon (France)		
Room B and Marquee	EB16	CAR T CELL THERAPY: FULL SPEED AHEAD R.J. Brentjens, New York, NY (USA)
	EB17	NEW DRUGS FOR OLD TARGETS G. Salles, Lyon (France)
	EB18	NEW DRUGS FOR NEW TARGETS A. Younes, New York, NY (USA)
12:00 – 17:00		
Marquee	Abstract Nr	<b>POSTER SESSION</b>
	136 - 159	BIOLOGY AND PATHOLOGY
	160 - 169	CLL
	170 - 183	INDOLENT LYMPHOMAS
	184 - 191	MANTLE CELL LYMPHOMAS
	192 - 206	AGGRESSIVE LYMPHOMAS
	207 - 217	EXTRANODAL LYMPHOMAS
	218 - 233	PTCL AND NK/T CELL LYMPHOMAS
	234 - 245	HODGKIN LYMPHOMAS
	246 - 262	IMMUNOTHERAPY
	263 - 285	NOVEL TREATMENTS

12:00 – 13:00

Marquee

**LUNCH TIME AND POSTER VIEWING**

13:00 – 14:00

Room A, B, Marquee,  
Cinema Corso, Auditorium  
and Aula Magna  
(USI Università)**OPENING OF THE CONFERENCE** 🗨️WELCOME AND INTRODUCTORY REMARKS  
F. Cavalli, Bellinzona (Switzerland)**HENRY KAPLAN MEMORIAL LECTURE AND  
SAN SALVATORE FOUNDATION PRIZE** 🗨️Introduction to San Salvatore Foundation:  
S. Coduri, Lugano (Switzerland)

Laudatio: R. Stahel, Zurich (Switzerland)

001

NEXT GENERATION CAR T CELLS FOR LYMPHOMA  
AND BEYOND

C.H. June, Philadelphia, PA (USA)

14:00 – 15:25

Room A, B, Marquee,  
Cinema Corso, Auditorium  
Aula Magna (USI Università)**PLENARY SESSION**Co-chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli,  
and Bellinzona (Switzerland)

14:00

004

IDENTIFYING MUTATIONS ENRICHED IN RELAPSED-  
REFRACTORY DLBCL TO DERIVE GENETIC FACTORS  
UNDERLYING TREATMENT RESISTANCE

C. Rushton, Burnaby, B.C (Canada)

14:15

005

ROBUST: FIRST REPORT OF PHASE III RANDOMIZED  
STUDY OF LENALIDOMIDE/R-CHOP (R2-CHOP) VS  
PLACEBO/R-CHOP IN PREVIOUSLY UNTREATED ABC-  
TYPE DIFFUSE LARGE B-CELL LYMPHOMA

U. Vitolo, Turin (Italy)

14:30

006

ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP)  
IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE  
LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT  
OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US  
INTERGROUP STUDY OF R2CHOP VS R-CHOP

G.S. Nowakowski, Rochester, MN (USA)

14:45

Discussant for presentations 004, 005 and 006:

M.A. Shipp, Boston, MA (USA)

15:00

007

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH  
ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE  
CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3  
DOUBLE-BLIND RANDOMIZED CLL12 TRIAL

P. Langerbeins, Cologne (Germany)

15:15

Discussant for presentation 007:  
S.M. O'Brien, Irvine, CA (USA)

15:25 – 15:50

Marquee

**COFFEE BREAK**

15:50 – 16:50

Room A, B, Marquee,  
Cinema Corso, Auditorium  
and Aula Magna  
(USI Università)

**AACR-ICML JOINT SESSION - THE ROLE OF NON-CLINICAL MODELS AS BRIDGES TO EARLY CLINICAL TRIALS**

Co-chairs: M. Foti, Philadelphia, PA (USA) and B. Nadel,  
Marseille (France)

15:50

008

DESIGNER ORGANOIDS FOR MODELING EPIGENETICS,  
SIGNALING, AND THERAPIES IN LYMPHOMA  
A. Singh, New York, NY (USA)

16:10

009

MOUSE PDX AS NON-CLINICAL MODELS FOR  
LYMPHOMA  
A. Louissaint, Boston, MA (USA)

16:30

010

ADVANCING OUR UNDERSTANDING AND TREATMENT  
OF LYMPHOMA WITH SPONTANEOUS CANINE MODELS  
L. Aresu, Turin (Italy)

17:05 – 18:05

**“FOCUS ON...” SESSIONS***5 parallel sessions*

Room A

**MANTLE CELL LYMPHOMA**

Chair: J.P. Leonard, New York, NY (USA)

17:05

011

COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR)  
IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED  
ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE  
CELL LYMPHOMA (MCL) – PHASE II TRIAL  
P. Jain, Houston, TX (USA)

17:15

012

IBRUTINIB WITH RITUXIMAB (IR) AND SHORT  
COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN  
PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE  
CELL LYMPHOMA (MCL)  
M. Wang, Houston, TX (USA)

17:25

013

AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST  
REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-  
FREE AND OVERALL SURVIVAL IN MANTLE CELL  
LYMPHOMA  
A. Zoellner, Munich (Germany)

17:35	014	OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY S. Le Gouill, Nantes (France)
17:45	015	ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Y. Song, Beijing (China)
17:55	016	OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY C. Visco, Verona (Italy)
Room B		<b>PET IMAGING</b> Chair: B.D. Cheson, Washington, D.C. (USA)
17:05	017	A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD B. Donati, Reggio Emilia (Italy)
17:15	018	PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)-POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION M. Novo, Rochester, MN (USA)
17:25	019	HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY L. Vercellino, Paris (France)
17:35	020	BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL M. Trněný, Prague (Czech Republic)
17:45	021	RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY S. Chauvie, Cuneo (Italy)

17:55	022	PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY P. Strati, Houston, TX (USA)
Cinema Corso		<b>PEDIATRIC LYMPHOMA</b> Chair: W. Wössmann, Hamburg (Germany)
17:05	023	NON-HODGKIN LYMPHOMA IN ADOLESCENT AND YOUNG ADULTS - A NATIONAL PROSPECTIVE POPULATION-BASED STUDY R. Carr, London (UK)
17:15	024	INCLUSION OF A PEDIATRIC PERSPECTIVE INTO RECOMMENDATIONS FOR THE INITIAL EVALUATION AND STAGING OF HODGKIN LYMPHOMA: A CALL TO ACTION FROM THE INTERNATIONAL SEARCH WORKING GROUP J. Flerlage, Memphis, TN (USA)
17:25	025	SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL) J. Flerlage, Memphis, TN (USA)
17:35	026	RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES K.M. Kelly, Buffalo, NY (USA)
17:45	027	IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY A. Burke, Cambridge (UK)
17:55	028	CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR REFRACTORY AND RELAPSED BURKITT'S LYMPHOMA, EARLY RESPONSE IN PEDIATRIC PATIENTS W.Q. Zhang, Beijing (China)
Auditorium (USI Università)		<b>RESULTS FROM SINGLE AGENT TRIALS</b> Chair: C. Thieblemont, Paris (France)



17:05	029	PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA K.A. Rogers, Columbus, OH (USA)
17:15	030	RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB S.D. Smith, Seattle, WA (USA)
17:25	031	A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) N. Kalakonda, Liverpool (UK)
17:35	032	TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY T.E. Witzig, Rochester, MN (USA)
17:45	033	DUVELISIB, AN ORAL DUAL PI3K- $\delta$ , $\gamma$ INHIBITOR, EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) PERIPHERAL T-CELL LYMPHOMA: RATIONALE FOR THE PHASE 2 PRIMO TRIAL S.M. Horwitz, New York, NY (USA)
17:55	034	EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY J. Scarisbrick, Birmingham (UK)
Aula Magna (USI Università)		<b>ONGOING TRIALS</b> Chair: J.M. Vose, Omaha, NE (USA)
17:05	OT01	NCRI PETReA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA A.R. Pettitt, Liverpool (UK)
17:15	OT02	POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL H. Tilly, Rouen (France)

17:25	OT03	PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R-CHOP VS PLACEBO/R-CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY) J. Zhu, Beijing (China)
17:35	OT04	THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS J.C. Villasboas, Rochester, MN (USA)
17:45	OT05	ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) T. Cummin, Southampton (UK)
17:55	OT06	TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA P. Porcu, Philadelphia, PA (USA)
18:30 – 20:00		<i>3 parallel symposia</i>
Room A		JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON <b>CHALLENGING THE STANDARDS OF CARE IN THE MANAGEMENT IN B-CELL LYMPHOMAS</b> Co-chairs: C. Buske, Ulm (Germany) and S. Rule, Plymouth (UK)
Room B		MEDSCAPE EDUCATION <b>CHALLENGING CURRENT PARADIGMS IN CLL: TIME AND TREATMENT</b> <i>Supported by an independent educational grant from AbbVie</i> Chair: P. Hillmen, Leeds (UK)
Auditorium (USI Università)		SANDOZ ONCOLOGY <b>VARIABILITY OF BIOLOGICS AND ITS IMPACT ON BIOSIMILAR DEVELOPMENT</b> Chair: P. Cornes, Bristol (UK)

08:00 – 08:45

**MEET THE PROFESSOR SESSIONS** 🎤

*5 parallel sessions*

Room A EB10

THE MODERN APPROACH TO MANTLE CELL LYMPHOMA  
S. Rule, Plymouth (UK)

Room B EB09

MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?  
S.V. Rajkumar, Rochester, MN (USA)

Cinema Corso EB01

PCNSL, A CURABLE DISEASE  
T.T. Batchelor, Boston, MA (USA)

Auditorium (USI Università) EB11

LIQUID BIOPSY IN NON-HODGKIN'S LYMPHOMA  
W.H. Wilson, Bethesda, MD (USA)

Aula Magna (USI Università) EB04

NEW TREATMENT OPTIONS IN HAIRY CELL  
LEUKEMIA WITH FOCUS ON BRAF INHIBITORS  
B. Falini, Perugia (Italy)  
*offered only once*

09:00 – 17.00  
Marquee

**OPENING OF POSTER SESSION AND EXHIBITION AREA**

09:00 – 10:30

**“CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)**

*4 parallel sessions*

Room A

**DLBCL**

Chair: L.H. Sehn, Vancouver, B.C. (Canada)  
Discussants: E. Giné Soca, Barcelona vs J.R. Westin,  
Houston

Cinema Corso

**HODGKIN LYMPHOMA**

Chair: A.S. LaCasce, Boston, MA (USA)  
Discussants: A.M. Sureda Balari, Barcelona vs H.J. Lee,  
Houston

Auditorium (USI Università)

**RADIOTHERAPY FOR LYMPHOMAS**

Chair: L. Specht, Copenhagen (Denmark)  
Discussants: T. Illidge, Manchester (UK) vs B.S. Dabaja,  
Houston

Aula Magna (USI Università)

**DIFFICULT PATHOLOGICAL CASES**

Chair: M. Ghielmini, Bellinzona (Switzerland)  
Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer,  
Basel (Switzerland) and P. Gaulard, Paris (France)  
Discussants: A. Lopez-Guillermo, Barcelona vs  
R. Hagemester, Houston

09:00 – 10:30 Room B and Marquee	Abstract Nr	<b>SESSION 1 – DLBCL: BIOLOGY</b> Co-chairs: R. Dalla-Favera, New York, NY (USA) and R. Küppers, Essen (Germany)
09:00	035	AN AUTOCHTHONOUS MOUSE MODEL OF MYD88 P.L265P- AND BCL2-DRIVEN DIFFUSE LARGE B CELL LYMPHOMA G. Knittel, Cologne (Germany)
09:15	036	CRYPTIC MYC AND BCL2 REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON-DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA L.K. Hilton, Burnaby, B.C. (Canada)
09:30	037	FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3' UTR MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA S.E. Arthur, Burnaby, B.C. (Canada)
09:45	038	THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) G. Sartori, Bellinzona (Switzerland)
10:00	039	TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA T. Röider, Heidelberg (Germany)
10:15	040	THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA S. Napoli, Bellinzona (Switzerland)
10:30 – 11:00 Marquee, Cinema Corso and USI Università		<b>COFFEE BREAK</b>

11:00 – 12:00

Room A, B, Marquee,  
Cinema Corso, Auditorium  
and Aula Magna  
(USI Università)**SESSION 2 – DLBCL: CLINICAL DATA**Co-chairs: M. Trněný, Prague (Czech Republic) and  
W. Zhao, Shanghai (China)

11:00

041

INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME  
AND METABOLIC HETEROGENEITY PREDICTS OUTCOME  
OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07  
STUDY COHORT

L. Ceriani, Bellinzona (Switzerland)

11:15

042

SMART START: RITUXIMAB, LENALIDOMIDE, AND  
IBRUTINIB ALONE PRIOR TO COMBINATION WITH  
CHEMOTHERAPY FOR PATIENTS WITH NEWLY  
DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

J.R. Westin, Houston, TX (USA)

11:30

043

RITUXIMAB MAINTENANCE FOR PATIENTS WITH  
DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST  
COMPLETE REMISSION: RESULTS FROM A  
RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP  
PHASE III STUDY

P. Lugtenburg, Rotterdam (Netherlands)

11:45

044

IMPAIRED IMMUNE HEALTH IN SURVIVORS OF  
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE  
POPULATION-BASED STUDY

T. Shree, Stanford, CA (USA)

12:00 – 13:00

Marquee

**LUNCH TIME AND POSTER VIEWING***from 12:30 to 13:00 authors in front of their poster for  
discussion with attendees*

12:00-13:00

Room E

**15-ICML PRESS CONFERENCE**

13:00 – 13:45

Room A, B,  
Marquee,  
Cinema Corso  
and Aula Magna  
(USI Università)**GIANNI BONADONNA MEMORIAL LECTURE** 🗣️*sponsored by the American Association for Cancer Research  
– AACR*

Laudatio: M.A. Shipp, Boston, MA (USA)

002

PRECISION EPIGENETIC THERAPY FOR B-CELL LYMPHOMA  
A.M. Melnick, New York, NY (USA)

13:45 – 15:15  
Room A, B, Marquee,  
Cinema Corso, Auditorium  
and Aula Magna  
(USI Università)

### SESSION 3 – CLL

Co-chairs: J.F. Seymour, Melbourne (Australia) and  
M. Hallek, Cologne (Germany)

13:45 045

INTERNATIONAL PROGNOSTIC SCORE FOR EARLY  
STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)  
A. Condoluci, Bellinzona (Switzerland)

14:00 046

FIXED-DURATION VENETOCLAX PLUS  
OBINUTUZUMAB IMPROVES PFS AND MINIMAL  
RESIDUAL DISEASE NEGATIVITY IN PATIENTS  
WITH PREVIOUSLY UNTREATED CLL AND  
COMORBIDITIES  
K. Fischer, Cologne (Germany)

14:15 047

GENETIC MARKERS AND OUTCOME IN THE CLL14  
TRIAL OF THE GCLLSG COMPARING FRONT LINE  
OBINUTUZUMAB PLUS CHLORABMUCIL OR  
VENETOCLAX IN PATIENTS WITH COMORBIDITY  
E. Tausch, Ulm (Germany)  
*Best abstract submitted by a young investigator/travel grant  
recipient*

14:30 048

ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB (IR)  
OR BENDAMUSTINE (BR) BY INVESTIGATOR CHOICE  
IN RELAPSED/REFRACTORY (R/R) CHRONIC  
LYMPHOCYTIC LEUKEMIA: PHASE 3 ASCEND  
STUDY  
P. Ghia, Milan (Italy)

14:45 049

ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR  
REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA  
W. Xu, Nanjing (China)

15:00 050

A PHASE 2 STUDY TO ASSESS THE SAFETY AND  
EFFICACY OF UMBRALISIB IN PATIENTS WITH  
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE  
INTOLERANT TO PRIOR BTK OR PI3K DELTA  
INHIBITOR THERAPY  
A.R. Mato, New York, NY (USA)

15:15 – 15:40  
Marquee

### COFFEE BREAK

15:40 – 16:55

*2 parallel sessions*Room A, Cinema Corso,  
Auditorium and Aula Magna  
(USI Università)**SESSION 4 – TREATMENT WITH NOVEL ANTIBODIES**Co-chairs: D.G. Maloney, Seattle, WA (USA) and  
P.L. Zinzani, Bologna (Italy)

15:40

051

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS  
R.H. Advani, Stanford, CA (USA)

15:55

052

CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)  
M.S. Topp, Würzburg (Germany)

16:10

053

CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA  
M.J. Dickinson, Melbourne (Australia)

16:25

054

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA  
J. Radford, Manchester (UK)

16:40

055

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)  
G. Collins, Oxford (UK)

15:40 – 16:55

**SESSION 5 – T-CELL LYMPHOMAS**

Room B and Marquee

Co-chairs: S. Luminari, Reggio Emilia (Italy) and  
K.J. Savage, Vancouver, B.C. (Canada)

15:40

056

RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.  
P. Ghione, New York, NY (USA)

15:55	057	AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY M. Lopez-Parra, Salamanca (Spain)
16:10	058	FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY O. Tournilhac, Clermont-Ferrand (France)
16:25	059	TREATMENT BENEFIT ASSOCIATING WITH NON-ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE S. Qi, Beijing (China)
16:40	060	SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4) R. Tao, Shanghai (China)
17:05 – 18:05		<b>“FOCUS ON...” SESSIONS</b> <i>5 parallel sessions</i>
Room A		<b>CLL AND MORE</b> Chair: D. Rossi, Bellinzona (Switzerland)
17:05	061	FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA A. Tedeschi, Milan (Italy)
17:15	062	HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL O. Al-Sawaf, Cologne (Germany)
17:25	063	IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY J. Wu, San Francisco, CA (USA)



17:35	064	AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL S. Handunnetti, Melbourne (Australia)
17:45	065	TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA T. Siddiqi, Duarte, CA (USA)
17:55	066	THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL E. Tiacci, Perugia (Italy)
Room B		<b>CHEMOTHERAPY-FREE STRATEGIES</b> Chair: J.W. Friedberg, Rochester, NY (USA)
17:05	067	PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK) A. Moccia, Bellinzona (Switzerland)
17:15	068	EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL F. Morschhauser, Lille (France)
17:25	069	AUGMENT PHASE III STUDY: LENALIDOMIDE/ RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/ PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS J.P. Leonard, New York, NY (USA)
17:35	070	INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA J. Sharman, Eugene, OR (USA)

17:45	071	RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY M.H. Delfau-Larue, Creteil (France)
17:55	072	SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. A. Stathis, Bellinzona (Switzerland)
Cinema Corso		<b>NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS</b> Chair: A. Davies, Southampton (UK)
17:05	073	PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION A.R. Mato, New York, NY (USA)
17:15	074	PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL S.D. Smith, Seattle, WA (USA)
17:25	075	ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) C.S. Tam, Melbourne (Australia)
17:35	076	A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW-GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS T. Shree, Stanford, CA (USA)
17:45	077	EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412) C. Diefenbach, New York, NY (USA)

17:55 078 HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS.  
T.E. Cummin, Southampton (UK)

Auditorium  
(USI Università)

**NON-CLINICAL NEW DRUGS**

Chair: L. Pasqualucci, New York, NY (USA)

17:05 079 FIRST-IN-CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN-HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY  
Y. Liu, New York, NY (USA)

17:15 080 COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB-VENETOCLAX RESISTANCE VIA TARGETING PI3K-AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA  
R. Zhang, Houston, TX (USA)

17:25 081 THE LANDSCAPE OF DRUG PERTUBATION EFFECTS IN LEUKEMIA AND LYMPHOMA  
T. Zenz, Zurich (Switzerland)

17:35 082 DISCOVERY OF A NOVEL, POTENTIAL FIRST-IN-CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS  
U. Philippiar, Bersee (Belgium)

17:45 083 KYM-001, A FIRST-IN-CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88-MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION  
J. Kelleher, Cambridge, MA (USA)

17:55 084 THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION  
C. Tarantelli, Bellinzona (Switzerland)

Aula Magna (USI Università)		<b>HIGH RISK LARGE B-CELL LYMPHOMAS</b> Chair: L.H. Sehn, Vancouver, B.C. (Canada)
17:05	085	EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY M.K. Gandhi, Brisbane (Australia)
17:15	086	YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS S. Leppä, Helsinki (Finland)
17:25	087	SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2-CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL G.S. Nowakowski, Rochester, MN (USA)
17:35	088	INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE-ADJUSTED R-EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC-043) M.S. Davids, Boston, MA (USA)
17:45	089	IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY F. Morschhauser, Lille (France)
17:55	090	CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES E.A. Chong, Philadelphia, PA (USA)
18:30 – 20:00		<i>2 parallel symposia</i>  CELGENE <b>INDIVIDUALIZING TREATMENT AND EMERGING THERAPIES IN B-CELL MALIGNANCIES</b> Chair: U. Vitolo, Turin (Italy)  MORPHOSYS <b>SURVIVAL, SAFETY, SIMPLICITY: TRANSFORMING TREATMENT SEQUENCING IN DLBCL</b> Co-chairs: B.D. Cheson, Washington DC (USA) and G. Salles, Lyon (France)

## Friday, June 21, 2019

08:00 – 08:45

### MEET THE PROFESSOR SESSIONS 🎤

*5 parallel sessions*

Room A

EB05

HOW TO APPROACH CLL IN CLINICAL PRACTICE

M. Hallek, Cologne (Germany)

Room B

EB02

DOUBLE HIT LYMPHOMA, SO WHAT?

A. Davies, Southampton (UK)

Cinema Corso

EB06

CUTANEOUS LYMPHOMAS

W. Kempf, Zurich (Switzerland)

Auditorium

EB07

MANAGING THE TOXICITIES OF CAR T-CELL THERAPY

(USI Università)

S.S. Neelapu, Houston, TX (USA)

Aula Magna

EB08

RARE B CELL LYMPHOMAS IN CHILDREN AND ADOLESCENTS

L. Quintanilla-Martinez de Fend, Tübingen (Germany) and  
W. Wössmann, Hamburg (Germany)

*offered only once*

09:00 – 18:30

Marquee

### OPENING OF POSTER SESSION AND EXHIBITION AREA

09:00 – 10:30

### “CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)

*3 parallel sessions*

Room A

#### FL / INDOLENT LYMPHOMA

Chair: S. Rule, Plymouth (UK)

Discussants: M. Provencio Pulla, Madrid vs L.J. Nastoupil,  
Houston

Cinema Corso

#### CLL

Chair: S.M. O'Brien, Irvine, CA (USA)

Discussants: J. Delgado, Barcelona vs P.A. Thompson,  
Houston

Aula Magna

(USI Università)

#### PTCL

Chair: K.J. Savage, Vancouver, B.C. (Canada)

Discussants: A. Martín, Salamanca vs N.H. Fowler, Houston

FRIDAY

09:00 – 10:30  
Room B and Marquee

### **SESSION 6 – LYMPHOMA PATHOLOGY**

Co-chairs: K. Ohshima, Kurume (Japan) and E. Campo, Barcelona (Spain)

- |       |     |   |
|-------|-----|---|
| 09:00 | 091 | DIAGNOSIS AND CLASSIFICATION ASSISTANCE FROM LYMPHOMA MICROSCOPIC IMAGES USING DEEP LEARNING<br>P. Brousset, Toulouse (France)  |
| 09:15 | 092 | INTEGRATING TUMOR- AND MICROENVIRONMENT- REFLECTING GENES IN A UNIQUE AND ROUTINE- APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL.<br>S.A. Pileri, Milan (Italy)                      |
| 09:30 | 093 | CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL<br>S. Balasubramanian, San Diego CA (USA)     |
| 09:45 | 094 | LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA<br>S. Araf, London (UK) |
| 10:00 | 095 | DEFINING BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATOPATHOLOGY DIAGNOSTIC SERVICE<br>S. Barrans, Leeds (UK)  |
| 10:15 | 096 | GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA<br>L. Quintanilla-Martinez de Fend, Tübingen (Germany)  |

09:00 – 12:00  
Auditorium  
(USI Università)

### **WORKSHOP – CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES**

Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG

**open to all 15-ICML attendees**

#### **Part 1: DOSE-FRACTIONATION ISSUES IN RADIOTHERAPY OF LYMPHOMAS**

Chair: M.K. Gospodarowicz, Toronto, ON (Canada)

- |       |   |
|-------|---|
| 09:00 | DOSE PER FRACTION, RESPONSE, LATE EFFECTS RELATIONSHIP IN LYMPHOMAS<br>R. Hoppe, Stanford, CA (USA) |
|-------|---|

09:20	OPTIMAL DOSE FRACTIONATION FOR INDOLENT AND AGGRESSIVE LYMPHOMAS P. Hoskin, London and Manchester (UK)
09:40	OPTIMAL DOSE FRACTIONATION IN HODGKIN LYMPHOMAS C. Baues, Cologne (Germany)
10:00 – 10:25	<b>COFFEE BREAK</b> <i>inside Auditorium (USI Università), for attendees</i>
10:25	<b>Part 2: RADIOTHERAPY IN THE ELDERLY LYMPHOMA PATIENT</b> LYMPHOMA IN THE ELDERLY - SCOPE OF THE PROBLEMS I. Glimelius, Uppsala (Sweden)
10:45	RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: INDOLENT LYMPHOMAS U. Ricardi, Turin (Italy)
11:00	RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: AGGRESSIVE LYMPHOMA J. Yahalom, New York, NY (USA)
11:15	RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: HODGKIN LYMPHOMA L. Specht, Copenhagen (Denmark)
11:30	RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: LATE EFFECTS D. Hodgson, Toronto, ON (Canada)
11:45	QUESTIONS
10:30 – 11:00	<b>COFFEE BREAK</b> Marquee, Cinema Corso and USI Università

11:00 – 12:00  
Room A, B, Marquee,  
Cinema Corso and  
Aula Magna (USI Università)

### SESSION 7 – HODGKIN LYMPHOMA

Co-chairs: R.H. Advani, Stanford, CA (USA) and T.A. Lister, London (UK)

11:00 097

STAGE I-II NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI-INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG

M.S. Binkley, Stanford, CA (USA)

11:15 098

NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP

S. Ansell, Rochester, MN (USA)

11:30 099

CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL

A. Gallamini, Nice (France)

11:45 100

COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA

A. Prica, Toronto, ON (Canada)

12:00 – 13:00  
Marquee

### LUNCH TIME AND POSTER VIEWING

*from 12:30 to 13:00 authors in front of their poster for discussion with attendees*

13:00 – 13:45  
Room A, B, Marquee,  
Cinema Corso and  
Aula Magna  
(USI Università)

### JOHN ULTMANN MEMORIAL LECTURE

*sponsored by the European School of Oncology – ESO*

Laudatio: J.M. Vose, Omaha, NE (USA)

003

THIRTY YEARS OF T-CELL LYMPHOMAS

P. Gaulard, Créteil (France)

13:45 – 15:00  
Room A  
and Cinema Corso

*4 parallel sessions*

### SESSION 8 – FOLLICULAR LYMPHOMA

Co-chairs: B.S. Kahl, St. Louis, MO (USA) and M. Herold, Erfurt (Germany)

13:45 101

PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY; A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL

S. Dirnhofer, Basel (Switzerland)



14:00	102	DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY P. Perez Galan, Barcelona (Spain)
14:15	103	IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA C.L. Batlevi, New York, NY (USA)
14:30	104	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI M. Federico, Modena (Italy)
14:45	105	INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA F. Morschhauser, Lille (France)
Room B and Marquee		<b>SESSION 9 - EXTRANODAL LYMPHOMAS</b> Co-chairs: M.K. Gospodarowicz, Toronto, ON (Canada) and E. Zucca, Bellinzona (Switzerland)
13:45	106	INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA A. Mottok, Ulm (Germany)
14:00	107	OUTCOME OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET-GUIDED APPROACH A. Hayden, Vancouver, B.C. (Canada)
14:15	108	NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY P.L. Zinzani, Bologna (Italy)
14:30	109	R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL A.J. Ferreri, Milan (Italy)

14:45	110	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER SOLID ORGAN TRANSPLANT (SOT): SURVIVAL AND PROGNOSTICATION AMONG 570 PATIENTS (PTS) TREATED IN THE MODERN ERA D. Jagadeesh, Cleveland, OH (USA)
14:15 – 17:30	Auditorium (USI Università)	<b>IBSA FOUNDATION SPECIAL FORUM - REVOLUTIONARY THERAPIES FOR CANCER</b> Chairmen: F. Cavalli, Bellinzona (Switzerland) and A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research <b>Open to all 15-ICML attendees, appreciated pre-registration at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)</b>
14:15		WELCOME AND INTRODUCTION S. Misiti, IBSA Foundation and A. Alimonti, IBSA Foundation Scientific Board
14:30		mTOR SIGNALING IN GROWTH AND METABOLISM M. Hall, Basel (Switzerland)
15:00		INNATE IMMUNITY, INFLAMMATION AND CANCER: FROM BENCH TO BEDSIDE A. Mantovani, Milan (Italy), London (UK)
15:30		BUILDING NEXT GENERATION CAR T CELLS C.H. June, Philadelphia, PA (USA)
16:00		FROM MOLECULAR ADDICTION TO IMMUNE ACTIVATION: REINVENTING THERAPIES FOR CANCER S. Peters, Lausanne (Switzerland)
14:15 – 17:15	Aula Magna (USI Università)	<b>UCLI-ICML JOINT SESSION – NEW DATA ON T-CELL AND OTHER LYMPHOMAS</b> Honorary Presidents: F. Cavalli, Bellinzona (Switzerland) and J. Ma, Harbin (China) Executive Presidents: W.J. Chng, Singapore (Singapore), J. M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China)
14:20	111	20-YEAR SURVIVAL DATA ANALYSIS OF PTCL PATIENTS IN PEKING UNIVERSITY CANCER HOSPITAL Y. Song, Beijing (China)
14:45	112	DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PTCL: LEVERAGING A LOGIC FOR PD1/PDL-1 INHIBITORS O.A. O'Connor, New York, NY (USA)

15:10	113	CLINICAL OUTCOME OF AN PROSPECTIVE, MULTICENTRE, RANDOMIZED, PHASE III NON-INFERIORITY CLINICAL TRIAL FOR PATIENTS WITH EXTRANODAL NK/T CELL LYMPHOMA TREATED BY P-GEMOX OR ASPAMETDEX H. Huang, Guangzhou (China)
15:35 – 15:55		<b>COFFEE BREAK</b> <i>inside Aula Magna (USI Università), for attendees</i>
15:55	114	NEW DATA IN THE MOLECULAR PATHOLOGY OF T CELL LYMPHOMAS L. de Leval, Lausanne (Switzerland)
16:20	115	DIFFUSE LARGE B-CELL LYMPHOMA: USING IMMUNE BIOMARKERS TO DEFINE NOVEL THERAPIES W. Zhao, Shanghai (China)
16:45	116	THE RELEVANCE OF OBSERVATIONAL REGISTRIES: THE CASE OF T CELL LYMPHOMA PROJECTS 1.0 AND 2.0 M. Federico, Modena (Italy)
15:00 – 15:30 Marquee		<b>COFFEE BREAK</b>
15:30 – 15:45 Room A, B, Marquee and Cinema Corso		<b>REPORT OF THE 15-ICML WORKSHOP</b> Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)
		BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE W.H. Wilson, Bethesda, MD (USA)
15:45 – 17:15 Room A, B, Marquee and Cinema Corso		<b>SESSION 10 – ADVANCES IN CAR T-CELL TREATMENT</b> Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)
15:45	117	NOVEL BAFF-R CAR T-CELL THERAPY FOR CD19 ANTIGEN-LOSS RELAPSED B CELL TUMORS L.W. Kwak, Duarte, CA (USA)

16:00	118	PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION C.L. Batlevi, New York, NY (USA)
16:15	119	CD30-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL) C.A. Ramos, Houston, TX (USA)
16:30	120	DURABLE RESPONSES AFTER CD19-TARGETED CAR-T CELL IMMUNOTHERAPY WITH CONCURRENT IBRUTINIB FOR CLL AFTER PRIOR IBRUTINIB FAILURE J. Gauthier, Seattle, WA (USA)
16:45	121	HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR-T CELL IMMUNOTHERAPY A.V. Hirayama, Seattle, WA (USA)
17:00	122	SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY T. Siddiqi, Duarte, CA (USA)
17:15 – 17:35		<b>SPECIAL LECTURE</b> Chair: F. Cavalli, Bellinzona (Switzerland)
Room A, B, Marquee and Cinema Corso		
	123	THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO? S.V. Rajkumar, Rochester, MN (USA)
17:35 – 18:30		<b>FAREWELL APERITIF</b>
Marquee		
18:30 – 19:30		<i>satellite symposium</i>
Room A		ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND – IOSI <b>“THE BIG DEBATE: POINT COUNTER POINT” ARE NEW EXPENSIVE ANTI-LYMPHOMA DRUGS WORTH THE MONEY?</b> <i>Supported by Gilead Sciences who provided funding</i> Chair: M. Ghielmini, Bellinzona (Switzerland)

08:30 – 10:30		<b>ESO – ESMIT Educational Session - PET-CT IN LYMPHOMA</b>
Auditorium (USI Università)		Chair: A.T. Lister, London (UK) Organized by the European School of Oncology – ESO and the European School of Multimodality Imaging & Therapy – ESMIT <b>Open to all 15-ICML attendees</b>
08:30		HOW TO INTERPRET PET-CT SCANS IN LYMPHOMAS: VISUAL AND FUNCTIONAL EVALUATION M. Meignan, Creteil (France)
08:50		PET-BASED CLINICAL DECISIONS: WHERE DO WE STAND AND WHERE WE MAY GO P.W.M. Johnson, Southampton (UK)
09:20		THE LUGANO CLASSIFICATION 5 YEARS AFTER: SHOULD WE CHANGE ANYTHING? B.D. Cheson, Washington, D.C. (USA)
09:40		CHALLENGING CASES FROM THE ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND - IOSI Presented by E. Zucca, Bellinzona (Switzerland) and L. Ceriani, Bellinzona (Switzerland) Discussants: A.T. Lister, London (UK) and all faculty
08:30 – 10:00		<b>SESSION 11 – NEW DRUG COMBINATIONS</b>
Room A and B		Co-chairs: A. Younes, New York, NY (USA) and M. Dreyling, Munich (Germany)
08:30	124	PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND) G. Salles, Lyon (France)
08:45	125	BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA M. Dickinson, Melbourne (Australia)
09:00	126	POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS C. Diefenbach, New York, NY (USA)

09:15	127	THE PI3KΔ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) A.D. Zelenetz, New York, NY (USA)
09:30	128	INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE S.M. Ansell, Rochester, MN (USA)
09:45	129	TARGETING THE PERIPHERAL T-CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5-AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL-MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY L. Falchi, New York, NY (USA)
10:15 – 11:15 Room A and B		<b>“FOCUS ON” SESSION</b> <b>INDOLENT NON-FOLLICULAR LYMPHOMA</b> Chair: G.S. Nowakowski, Rochester, MN (USA)
10:15	130	EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT A. Conconi, Ponderano (Italy)
10:25	131	INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL A.J. Ferreri, Milan (Italy)
10:35	132	MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY A. Bruscazzin, Bellinzona (Switzerland)
10:45	133	UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY P.L. Zinzani, Bologna (Italy)

10:55 134 IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY  
J. Castillo, Boston, MA (USA)

11:05 135 IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA: FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821)  
S.P. Treon, Boston, MA (USA)

11:15 – 11:40  
Room A and B

### 15-ICML HIGHLIGHTS

“TAKE HOME MESSAGES”

J.W. Friedberg, Rochester, NY (USA)

11:40 – 11:50

CLOSURE AND FAREWELL


F. Cavalli, Bellinzona (Switzerland)

13:30 – 18:00  
Room B

### IV INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA - HOW TO STAGE CANINE LYMPHOMA IN 2019

Co-chairs: L. Aresu, Turin (Italy), S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)

Organized by the European Canine Lymphoma Network  
**open to all 15-ICML attendees**

 This icon denotes presentations that will be audio- and video-recorded and available online, only for 15-ICML attendees, starting from July 2019, thanks to an unrestricted grant provided by



A member of the AstraZeneca Group

NB: please note that this version of the program does not include changes communicated to 15-ICML Secretariat after May 22 (date of printing). You can find the definitive version on the ICML website ([www.lymphcon.ch](http://www.lymphcon.ch)) and in the 15-ICML APP.

## 15-ICML TRANSPORT INFORMATION

A 15-ICML Transport Info Desk is available in Palazzo dei Congressi, with the same working hours as the Registration Desk.

15-ICML attendees who booked their accommodation in Ticino (the region where Lugano is the main town) will receive UPON HOTEL CHECK-IN the “TicinoTicket”, a public transport ticket, valid for the length of their stay and valid on all the public transports in Ticino.

For further information on “Ticino Ticket” please visit <http://www.ticino.ch/en/ticket.html>

### 15-ICML TRANSPORT SERVICE

For those hotels which are not in Ticino or are not very well served by public transports (and only for those who confirmed the hotel reservation through Amiconi Consulting SA), ICML Secretariat organize bus connections at given times..

The arrival / departure point is CAMPO MARZIO PARKING.

The buses schedule and timetable is available at the ICML official website ([www.lymphcon.ch](http://www.lymphcon.ch)), on the 15-ICML APP and at the Transport Info Desk.

### PRIVATE TRANSPORTS

Viale Cattaneo, the street connecting Lugano city center to Castagnola and running along Palazzo dei Congressi and Parco Ciani, is a two-way street.

During ICML, it will be one way only (direction: from city center to Castagnola) from Tuesday 18 to Friday 21 from 17:00 to 21:00, to permit private transport passenger boarding and alighting.

Outside this allowed time slot, Campo Marzio Parking is the passenger boarding and alighting appointed space.

### 15-ICML SHUTTLE SERVICE

A shuttle service connects the conference locations with the following timetable:

- on Tuesday, June 18, from 18:00 to 21:00
- from Wednesday, June 19 to Friday, June 21, from 07:30 to 21:00
- on Saturday, June 22, from 07:30 to 10:30

Please note that, on this service, attendees with physical disabilities have precedence.





A cable railway connects Lugano Train Station to the center of the city, running daily from 07:00 to 19:00 (on Thursday, June 20 and Saturday, June 22 from 08:00 to 16:00 only).

Lugano City Taxis (ph. **+41 91 922 8833**) are available outside the main entrance of Palazzo dei Congressi.

## FURTHER INFORMATION

Thursday, June 20 is bank holiday in Ticino: shops may be closed and public transportation will run less frequently than on ordinary working days.

Lugano lakefront street, from Lugano Arte e Cultura - LAC (Piazza Bernardino Luini 6), to Piazza Castello, will be closed to traffic on Friday, June 21 as of 19:30. Public and private transports will be diverted to alternative routes.

### Insurance

The 15-ICML Organizers bear no responsibility for untoward events in connection with, before, during and after the congress. Participants are strongly advised to take out their own personal and travel insurance coverage.

*NB: charge of replacement of lost badge: CHF 100.*



## 15-ICML CONTACTS



### FOUNDATION FOR THE INSTITUTE OF ONCOLOGY RESEARCH (IOR)

Via Vincenzo Vela 6, 6500 Bellinzona, VAT CHE-110.407.651 IVA

#### PRESIDENT

Franco Cavalli, Bellinzona (Switzerland)

Tel: +41 91 811 86 66

Fax: +41 91 811 80 56

franco.cavalli@eoc.ch

#### ORGANIZING COMMITTEE CHAIRMAN

Michele Ghielmini, Bellinzona (Switzerland)

Tel: +41 91 811 94 10

Fax: +41 91 811 87 31

michele.ghielmini@eoc.ch

#### ICML SECRETARIAT

- Cristiana Brentan

*general coordination and information, scientific program, abstracts*

cristiana.brentan@lymphcon.ch

- Orietta Lugli

*exhibition management, satellite symposia, sponsorships, ancillary meetings*

orietta.lugli@lymphcon.ch

- Chiara Saporiti

*group and individual registrations, accounting*

registrations@lymphcon.ch

Tel: +41 91 922 05 75

## 15-ICML PARTNERS



**EVENTMORE**  
tecnica eventi-spettacoli-congressi

**Eventmore**

Via S. Gottardo 18D  
CH-6532 Castione

Tel: +41 91 850 10 60  
Fax: +41 91 850 10 61  
E-mail: [info@eventmore.ch](mailto:info@eventmore.ch)  
Website: [www.eventmore.ch](http://www.eventmore.ch)

In charge of any technical aspect of conference sessions, satellite symposia and ancillary meetings held in Palazzo dei Congressi, Marquee Parco Ciani, USI Università, Cinema Corso and Villa Ciani

**AM  
I  
C  
O  
N  
I  
S/A**  
Your partner for Events

In charge of hotel accommodation and ICML Climate Protection Run. Amiconi Consulting SA can also provide the following services: meeting facilities (outside the Conference Venue), dinner reservations for groups, transfers services from/to the hotels/restaurants and the conference centre.

**Amiconi Consulting SA**

Via al Forte 10  
CH - 6900 Lugano

Tel. +41 (0)91 921 38 12  
Fax +41 (0)91 921 3813  
[info@amiconiconsulting.ch](mailto:info@amiconiconsulting.ch)  
[www.amiconiconsulting.ch](http://www.amiconiconsulting.ch)



# FOREFRONT

## IN HODGKIN LYMPHOMA

*Science. Progress. Care.*

Seattle Genetics and Takeda Oncology are leading the way to a better understanding of classical Hodgkin lymphoma by expanding knowledge around the biological development of the disease and the critical role of CD30. By driving science forward, we are helping to address the unanswered questions to improve the treatment of Hodgkin lymphoma.

Our commitment to advancing care for people living with Hodgkin lymphoma is demonstrated by more than 50 clinical trials, including two large, randomized, phase III company-sponsored studies. We take pride in providing unparalleled support for clinical research in Hodgkin lymphoma with the goal of improving outcomes for patients around the world.

Patients are at the center of our mission. We work alongside advocacy groups to improve the patient experience and outcomes by advancing education and identifying and addressing their unmet needs.

Join our journey at the forefront of science, progress, and care by visiting us at [seattlegenetics.com](http://seattlegenetics.com) and [takedaoncology.com](http://takedaoncology.com).



ONCOLOGY

All trademarks are the property of their respective owners.  
©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.  
All rights reserved.  
08/18 GON/NON/15/0050a(2)